NUVO A Division Of INTAS

With a global turnover of $2.3 billion, we have a strong presence in key markets across 85+ countries. We spearhead every endeavour with the power of human expertise, innovative research and advanced technology, aiming to set new benchmarks in global healthcare continually. Each of our 16 ultra-modern facilities is a testament to our uncompromising quality standards. All these facilities are approved by major global regulatory agencies including the US-FDA, UK-MHRA, TGA (Australia), MCC (S. Africa), TPD (Canada), MEB (Netherlands), AFI (Belgium), FDA (Nordic Countries), ANVISA (Brazil), and WHO-GMP. Intas was the first company to receive European Health Authority accreditation for its biologics manufacturing facility in India. While we have a strong presence in CNS, CVS, and chronic markets in India, we specialize and offer a wide range of products in Oncology and other hospital-based therapeutic segments in the EU and US.